Quick Answer
Apogee Therapeutics, Inc. reported Net Income of -$255.84 million for fiscal year 2025.
Apogee Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$255.84M | -40.5% |
| 2024 | -$182.15M | -116.9% |
| 2023 | -$83.98M | -111.1% |
| 2022 | -$39.78M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$65.02M | -32.6% | +1.6% |
| June 30, 2025 | -$66.10M | -95.5% | -19.4% |
| March 31, 2025 | -$55.34M | -72.4% | -12.9% |
| September 30, 2024 | -$49.02M | -135.2% | -45.0% |
| June 30, 2024 | -$33.82M | -79.1% | -5.4% |
| March 31, 2024 | -$32.09M | -156.2% | -54.0% |
| September 30, 2023 | -$20.84M | -6.0% | -10.4% |
| June 30, 2023 | -$18.89M | -939.9% | -50.8% |
- Apogee Therapeutics, Inc. showed a decrease of -40.5% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Apogee Therapeutics, Inc.’s net income has declined by 543.1% (from -$39.78 million to -$255.84 million).
- The most recent figure is from Apogee Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: